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Abstract Caspase-1 (interleukin-1L-converting enzyme) is re-
ported to play an important role in the regulation of apoptosis.
We investigated the inhibition of caspase-1 by the cell permeable
caspase-1 inhibitor Ac-AAVALLPAVLLALLAP-YVAD.CHO
in pancreatic carcinoma cells. Inhibition of caspase-1 induced a
non-apoptotic/‘necrotic-like’ cell death in AsPC-1, BxPC-3,
MiaPaCa-2 and Panc-1 cells. Expression levels of bcl-2 and bax
were up-regulated in caspase-1 inhibitor-treated cells while that
of bcl-xL remained unaltered. Our observations support our
previous findings that caspase-1 is potentially involved in anti-
apoptotic processes in pancreatic carcinoma. ß 2001 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Caspase-1 was the ¢rst identi¢ed member of a large family
of cysteine proteases whose members play distinct roles in
in£ammation and apoptosis [1]. Caspases were implicated in
apoptosis with the discovery that CED-3, the product of a
gene required for cell death in the nematode Caenorhabditis
elegans, is related to mammalian interleukin-1L (IL-1L)-con-
verting enzyme (ICE, caspase-1) [2].
However, in recent studies we could demonstrate that ICE
is overexpressed in the adenocarcinomas of the pancreas and
correlated signi¢cantly with the overexpression of epidermal
growth factor (EGF), EGF receptor and cyclin D1, pointing
to possible aspects of ICE in proliferative processes in human
pancreatic carcinoma cells [3]. This suggestion was also sup-
ported by experiments in EGF-stimulated pancreatic AsPC-1
cells demonstrating the reduction of cell proliferation by cas-
pase-1 inhibition [4].
Peptide inhibitors designed to mimic known sequences of
caspase substrates have been shown to suppress or alter e¡ec-
tively caspase-dependent e¡ects in a number of cells [5]. In
this study we used the polypeptide Ac-AAVALLPAVLLAL-
LAPYVAD-CHO (p-YVAD.CHO) which is reported to be a
speci¢c cell permeable inhibitor of caspase-1 [6,7]. The C-ter-
minal YVAD.CHO region is a highly speci¢c, potent and
reversible inhibitor of caspase-1. The long hydrophobic N-
terminal sequence (residues 1^16) corresponds to the hydro-
phobic region of the signal peptide of the Kaposi ¢broblast
growth factor and confers cell permeability to the peptide
without cytotoxic e¡ects [8].
Members of the bcl-2 family proteins are key regulators of
apoptosis and some of them are involved in necrosis as well
[9,10]. Some of these proteins undergo post-translational mod-
i¢cation, such as phosphorylation or proteolysis, that serves
to alter their functions in some fashion [11^13]. Pro- and anti-
apoptotic members can also heterodimerize and seemingly
titrate one another’s function, suggesting that their relative
concentration may act as a rheostat for the suicide program
[14].
In this study we investigated the in£uence of caspase-1 in-
hibition on the cell cycle of the pancreatic carcinoma cells
AsPC-1, BxPC-3, MiaPaCa-2 and Panc-1 and the expression
pattern of bcl-2 family proteins in these cells with and without
caspase-1 inhibition.
2. Materials and methods
2.1. Cell culture
AsPC-1 cells were grown in monolayers at 37‡C in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum (FCS), penicillin/streptomycin and glutamine (Biochrom,
Berlin, Germany). Cells were seeded at a density of about 3U105 cells
in 50 mm (q) plates, starved for 24^30 h and then incubated with
EGF (25 ng/ml in FCS-free DMEM). To investigate functional prop-
erties of caspase-1, the following cell permeable caspase inhibitors
were used: caspase-1 inhibitor I (p-YVAD.CHO), caspase-1 inhibitor
II (Ac-YVAD.cmk), caspase inhibitor III (Boc-D(OMe)-fmk), cas-
pase-1 inhibitor IV (Ac-YVAD.aom), caspase-1 inhibitor VI (Z-YVA-
D(OMe)-fmk) and caspase-4 inhibitor I (Ac-AAVALLPAVLLAL-
LAP-LEVD.CHO, p-LEVD.CHO) (Calbiochem). Cells were
incubated with EGF (25 ng/ml) and a caspase inhibitor (dissolved
in dimethyl sulfoxide, DMSO) or DMSO alone in DMEM. The in-
hibitors p-YVAD.CHO and p-LEVD.CHO were used in a concentra-
tion of 25 WM, the others in a concentration between 100 and 200 WM.
After incubation, cells were collected by mechanical scraping and used
for Western blot or cell cycle analyses. All of the results were vali-
dated in at least three independent experiments.
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2.2. Reverse transcription (RT) and polymerase chain reaction (PCR)
mRNA was isolated using a guanidinium thiocyanate method and
oligo(dT)-cellulose column chromatography (QuickPrep, Micro
mRNA Puri¢cation Kit; Pharmacia Biotech). The mRNA was dis-
solved in the elution bu¡er (30 Wl) provided in the kit. cDNA was
prepared by RT of mRNA using SuperScript RT RNase-H-reverse
transcriptase (Life Technologies). A 399 bp ICE fragment was ampli-
¢ed using the following primers: 5P-GGAAATTACCTTAATATG-
CAAGAC-3P (sense) and 5P-CATGAACACCAGGA-ACGTGCT-
GTC-3P (antisense). A 5 Wl aliquot of cDNA was ampli¢ed under
the following cycling conditions: 94‡C for 60 s, 55‡C for 30 s and
72‡C for 120 s for 40 cycles. The PCR products were electrophoresed
through a 1% agarose gel containing ethidium bromide and visualized
by UV light. L-Actin was used as an internal standard to con¢rm
equal loading in each experiment.
2.3. Western blot analysis
Cells were lysed in 10 mM Tris pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100, and 1 Wg (each) of aprotinin, leupeptin
and pepstatin/ml. 10 Wg protein of each sample were loaded on a
denaturing 15% polyacrylamide gel. After electrophoresis the resolved
proteins were transferred on a nitrocellulose membrane (Schleicher
and Schuell) using a semi-dry transblot apparatus (Phase; Lu«beck,
Germany). Non-speci¢c protein interactions were blocked by pre-in-
cubation of the membranes with 5% skim milk in phosphate-bu¡ered
saline (PBS) overnight at 4‡C. After incubation of the membranes
with antibodies, speci¢c binding was detected using the enhanced
chemiluminescence system (Amersham). The monocytic cell line
BJAB served as a positive control for bcl-2 and bcl-xL. Blots were
re-probed with an antibody against actin (Ser-Gly-Pro-Ser-Ile-Val-
His-Arg-Lys-Cys-Phe, Sigma) to control for equal protein loading
of the gel. The rabbit polyclonal serum of anti-bcl-xL (H-5), were
purchased from Santa Cruz Biotechnology (CA, USA), mouse mono-
clonal antibodies against bcl-2 (Ab-1) and bax (Ab-5) from Calbio-
chem.
2.4. Immunostaining
Cells were ¢xed with 70% ethanol for 20 min at 320‡C, washed
twice with PBS and incubated with anti-bcl-2 (Ab-1, Calbiochem),
anti-bcl-xL (H-5), and anti-bax (B-9) (Santa Cruz Biotechnology,
CA, USA) at 37‡C followed by incubation with rhodamine or
DTAF-conjugated secondary antibody for 1 h at 37‡C. Stained cells
were visualized under a £uorescence microscope.
2.5. Cell cycle analysis
For cell cycle analysis, cell nuclei were stained with propidium
iodide using Cell Cycle Plus (Becton and Dickinson). Analysis was
performed by £ow cytometry carried out on a FACScan using the
Cell Quest program (Becton and Dickinson). For determination of
cell size, trypsinated unstained cells were used. Cell cycle experiments
were performed in a total of ¢ve independent experiments.
2.6. Caspase-1 activity assay
To con¢rm selectivity of the inhibitor p-YVAD.CHO for caspase-1
under our experimental conditions, i.e. in EGF-treated AsPC-1 cells,
we performed the caspase-1 colorimetric assay (RpD Systems, Ger-
many) according to the manufacturer’s protocol. Brie£y, 24 h after
incubation of EGF-stimulated AsPC-1 cells with 25 WM p-YVAD.-
CHO, cells were lysed and then incubated with a caspase-1-speci¢c
substrate, the peptide WEHD-p-nitroanilide, for 1^2 h at 37‡C. Cleav-
age of the peptide by active caspase-1 releases the chromophore p-
nitroanilide, which can be quantitated spectrophotometrically at 405
nm. The level of caspase enzymatic activity in the cell lysate is directly
proportional to the color reaction.
2.7. Apoptosis assay
To detect morphological changes in the nuclear chromatin of cells
undergoing apoptosis, cells were stained with the DNA-binding £uo-
rochrome bis-benzimide (Hoechst 33258; Sigma). Cells were ¢xed
with 3.7% paraformaldehyde in PBS for 15 min and washed twice
with PBS. Staining of the nuclei was performed by incubation of
the cells with bis-benzimide (15 Wg/ml) for 15 min followed by wash-
ing with PBS. A 5 Wl aliquot of cells was placed on a glass slide and
the average number of nuclei per ¢eld was scored for the incidence of
condensed chromatin fragments in apoptotic cells under a £uores-
cence microscope.
2.8. DNA fragmentation assay
DNA was extracted from 4U105 cells using the apoptotic DNA
ladder Kit (Roche, Switzerland). Isolated DNA was electrophoresed
through a 1% agarose gel containing ethidium bromide and visualized
by UV light. L-Actin was used as an internal standard to con¢rm
equal loading in each experiment.
2.9. Statistical analysis
For statistical analysis the paired Student’s t-test was used. Signi¢-
cance was de¢ned as P6 0.05.
3. Results
3.1. p-YVAD.CHO induces cell death in AsPC-1 cells
As we have previously shown, EGF-stimulated AsPC-1 cells
express caspase-1 in its active form as demonstrated by the
detection of the proteolytically active subunits p20 and p10,
the caspase-1-dependent fragmentation of lamin A/C and the
detection of active IL-1K and IL-1L without leading to cell
death [4]. In order to induce expression of active caspase-1,
AsPC-1 cells were stimulated with 25 ng/ml EGF and incu-
bated with the caspase-1 inhibitor p-YVAD.CHO (25 WM) or
DMSO alone for 0, 6, 12, 18, 24 and 48 h. Approximately 6 h
after incubation inhibitor-treated cells began to detach from
the matrix surface displaying typical morphological evidence
for cell death. Detached cells were stained with 0.2% trypan
blue and counted in a hemocytometer. The observed cell
death occurred highly signi¢cant after 18 h (15.8 þ 3%,
P6 0.02), 24 h (24.5 þ 10.3%, P6 0.01) and 48 h (25.4 þ 3%,
P6 0.005) of inhibitor incubation. The ratio between de-
tached (dead) cells and total cell amount treated with p-
YVAD.CHO is compared to that of the DMSO-treated cells
in Fig. 1. We also tested other caspase-1 inhibitors: Ac-
YVAD.cmk (200 WM), Ac-YVAD.aom (100 WM) and Z-
YVAD(Ome)-fmk (100 WM) and the pan-caspase inhibitor
Boc-D(OMe)-fmk (100 WM). Only p-YVAD.CHO had a sig-
ni¢cant cell-death e¡ect on pancreatic AsPC-1 cells. As we
demonstrated in previous work, Ac-YVAD.cmk induces a sig-
Fig. 1. Incubation with p-YVAD.CHO induces cell death in EGF-
stimulated AsPC-1 cells. Ratio of detached (dead) AsPC-1 cells to
total cell amount after incubation with EGF (25 ng/ml) and
p-YVAD.CHO (25 WM) or DMSO alone for 0, 6, 12, 18, 24 and
48 h. The data represent the mean þ S.D. of at least four independ-
ent experiments (P-values as indicated).
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ni¢cant reduction of cell proliferation on EGF-stimulated
AsPC-1 cells and a slight increase of the apoptotic fraction
although it did not reach statistical signi¢cance [4]. Inhibitors
Ac-YVAD.aom (100 WM), Z-YVAD(Ome)-fmk (100 WM) and
Boc-D(OMe)-fmk (100 WM) did not display any cell-death
e¡ect on AsPC-1 cells.
In order to con¢rm the selectivity of p-YVAD.CHO for
caspase-1 and its inhibition under our experimental condi-
tions, i.e. in EGF-stimulated AsPC-1 cells, we measured cas-
pase-1 activity by a colorimetric assay described in Section 2.
Absorption at 405 nm indicating the caspase-1-dependent re-
lease of the chromophore p-nitroanilide which is directly pro-
portional to caspase-1 activity is signi¢cantly reduced
(P6 0.05) in EGF-stimulated AsPC-1 cells 24 h after incuba-
tion with 25 WM p-YVAD.CHO as compared to EGF-stimu-
lated AsPC-1 cells treated with DMSO alone.
To examine whether caspase-4, which shares similar sub-
strate speci¢cities with caspase-1 [6,7], is also involved in the
induction of the observed cell death, AsPC-1 cells were incu-
bated with caspase-4 inhibitor p-LEVD.CHO, a polypeptide
with the same hydrophobic N-amino-terminal tail (residues 1^
16) as the caspase-1 inhibitor p-YVAD.CHO. The amount of
detached (dead) cells after incubation with 25 WM p-LEV-
D.CHO is similar to that of DMSO-treated cells in EGF-
stimulated AsPC-1 cells. Hence, involvement of caspase-4 in
the p-YVAD.CHO-induced cell death is very unlikely. This
¢nding excludes also the cytotoxicity of the hydrophobic tail
of the polypeptide itself.
Incubation with p-YVAD.CHO (25 WM) also induced sig-
ni¢cant cell death in EGF-stimulated (caspase-1-expressing)
pancreatic BxPC-3 (P6 0.01) and Panc-1 (P6 0.05) cells
whereas in MiaPaCa-2 cells the observed cell death did not
reach statistical signi¢cance (P = 0.06) (Fig. 2A,B). The activ-
ity of caspase-1 and its inhibition in these cells after 24 h was
con¢rmed by the colorimetric caspase-1 activity assay de-
scribed above. In the presence of p-YVAD.CHO, caspase-1
activity was signi¢cantly reduced (P6 0.05).
3.2. Evidence of a non-apoptotic/necrotic cell death
In order to characterize the mode of cell death induced by
Fig. 2. Induction of cell death in EGF-stimulated AsPC-1, BxPC-3,
MiaPaCa-2 and Panc-1 cells 24 h after incubation with p-YVAD.-
CHO. A: Expression of caspase-1 mRNA in AsPC-1 (lane 1), Mia-
PaCa-2 (lane 2), Panc-1 (lane 3) and BxPC-3 (lane 4) after incuba-
tion with EGF (25 ng/ml) and p-YVAD.CHO (25 WM) for 24 h.
Equal loading was con¢rmed by L-actin mRNA analysis. L, 100 bp
DNA ladder. B: Cell death in AsPC-1, BxPC-3, MiaPaCa-2 and
Panc-1 determined as the ratio of detached (dead) cells to total cell
amount in the absence or the presence of 25 WM p-YVAD.CHO
after 24 h (S.D. and P-values as indicated; n.s.: not signi¢cant).
Fig. 3. Induction of a necrotic-like cell death in EGF-stimulated AsPC-1 after treatment with the caspase-1 inhibitor p-YVAD.CHO. A: Aga-
rose gel electrophoresis of total DNA from EGF-stimulated (25 ng/ml) AsPC-1 cells cultured for 48 h in the presence and the absence of 25
WM p-YVAD.CHO. L, 100 bp DNA ladder. B: Determination of AsPC-1 cell size after incubation with p-YVAD.CHO (25 WM) or DMSO:
histogram of FSC light intensity of analyzed EGF-stimulated (25 ng/ml) AsPC-1 cells in the presence and the absence of 25 WM p-YVAD.CHO
for 24 h. FSC light intensity is related to cell size. Incubation with p-YVAD.CHO leads to a signi¢cant increase in cell size (9.4 þ 1.4%;
P6 0.01, t-test).
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p-YVAD.CHO we performed an apoptosis assay using bis-
benzimide for the detection of condensed nuclear chromatin
indicating apoptosis. We observed no di¡erence between in-
hibitor-treated and -untreated EGF-stimulated AsPC-1 cells.
In both cases the amount of condensed (apoptotic) nuclei was
lower than 6%. This ¢nding was con¢rmed by cell cycle anal-
ysis where negligible sub-G1 fractions could be observed (data
not shown).
DNA fragmentation assays of p-YVAD.CHO-treated cells
failed to display the enzymatic cleavage of DNA into multi-
mers of 180 bp fragments (‘DNA ladder’) typical for apopto-
sis. In contrast DNA appears as a continuous spectrum of
sizes resulting in a smear, pointing to DNA fragmentation
during necrosis (Fig. 3A).
Another e¡ect of p-YVAD.CHO was observed regarding
cell size. The size of AsPC-1 cells in the presence and the
absence of p-YVAD.CHO was determined in the £ow cytom-
eter. In EGF-stimulated AsPC-1 cells incubated with 25 WM
p-YVAD.CHO for 24 h, a signi¢cant increase of cell size
could be observed (9.4 þ 1.4%; P6 0.01, t-test) detected as
an increase in intensity of the FSC light measured in the
£ow cytometer which can be interpreted as cell swelling dur-
ing necrosis [15] (Fig. 3B). The intensity of the SSC light
which correlates to the granularity of the cells was unaltered
as compared to the cells treated with DMSO alone indicating
the lack of formation of apoptotic bodies (data not shown).
3.3. Expression of bcl-2 and bax is up-regulated in caspase-1
inhibitor-treated cells
The expression pattern of bcl-2 family proteins known to be
involved in the regulation of cell-death processes was deter-
mined by Western blot analysis. Cells were stimulated with 25
ng/ml EGF and incubated with 25 WM p-YVAD.CHO or
DMSO alone for 0, 6, 12, 18 and 24 h. In caspase-1 inhib-
itor-treated cells the expression of bcl-2 and bax protein was
up-regulated as compared to EGF-stimulated cells incubated
with DMSO alone whereas expression levels of bcl-xL re-
mained unaltered.
In order to con¢rm our observations from Western blot
analysis immuno£uorescence staining was also performed us-
ing speci¢c antibodies for bcl-2, bax and bcl-xL. EGF-stimu-
lated AsPC-1 cells incubated with 25 WM p-YVAD.CHO dis-
play a higher immuno£uorescence reactivity for bax and bcl-2
than untreated cells whereas that of bcl-xL remained un-
changed (data not shown).
Expression levels of bcl-2 and bax protein were also up-
regulated in EGF-stimulated BxPC-3 and MiaPaCa-2 cells,
after incubation with p-YVAD.CHO. In Panc-1 cells no dif-
ference in bax expression could be observed between inhibi-
tor-treated and -untreated cells whereas only very low levels of
bcl-2 could be detected. In all examined pancreatic cells bcl-xL
levels remain unchanged (data not shown).
4. Discussion
In recent studies we could demonstrate that stimulation
with EGF induces a time-dependent expression of active cas-
pase-1 in AsPC-1 cells without leading to cell death [4]. Here
we investigated the in£uence of the cell permeable p-YVAD.-
CHO on the cell cycle of pancreatic carcinoma cell lines. We
demonstrated that incubation with caspase-1 inhibitor, p-
YVAD.CHO, signi¢cantly induces cell death in EGF-stimu-
lated caspase-1-expressing AsPC-1 cells. Cells incubated with
the inhibitor are larger in size than untreated cells that can be
interpreted as cell swelling during necrosis [15] (Fig. 2). The
absence of a DNA ‘ladder’, chromatin condensation and sub-
G1 events are also evident for a non-apoptotic/‘necrotic-like’
cell death after caspase-1 inhibition. These results seem to be
in contradiction with the general assumption that inhibition of
caspases would rescue cells from death. However, a similar
observation was made in thymocytes where treatment with a
broad spectrum caspase inhibitor leads also to a necrotic cell
death [16]. In camptothecin-treated leukemia U-937 cells, the
inhibition of caspase activities is coupled with a shift from
apoptosis to transient G1 arrest followed by massive necrosis
[18]. In B-lymphocytes, the inhibition of caspase activity also
induces a switch from apoptotic death to a necrotic form
suggesting that apoptosis and necrosis share common initia-
tion pathways [17]. The necrotic e¡ect of p-YVAD.CHO in
pancreatic AsPC-1 cells as compared to other tested caspase-1
inhibitors may be partially due to its nuclear permeability
provided through the hydrophobic polypeptide tail as demon-
strated by Lin et al. [8]. As we know from our immunohisto-
chemical studies in pancreatic carcinoma tissues the overex-
pression of caspase-1 is cytoplasmatic and nuclear as well in
pancreatic tumor cells [3].
Searching for factors potentially in£uencing the balance be-
tween cell survival and cell death we examined the expression
pattern of bcl-2 family proteins known to be involved in the
regulation of cell death in its apoptotic and necrotic form as
well [9,10]. Interestingly, incubation with the caspase-1 inhib-
itor is accompanied by an upregulation of the ‘anti-apoptotic’
bcl-2 protein in AsPC-1 cells (Fig. 3). An increased bcl-2 ex-
pression was also found in apoptotic and necrotic brain tissue
after head injury [10], in macrophages after Shigella-induced
apoptosis [19] as well as in necrotic muscle ¢bers in several
human myopathies [20]. However, some reports speculate that
the anti-cell-death function of bcl-2 depends not on the ex-
pression level but on its phosphorylation state [11,12]. Other
studies presented a model in which the ratio of bcl-2 to its
heterodimerization partner bax determines survival or death
following a cell-death stimulus [14] whereas investigations in
U251 glioblastoma cells demonstrated that the anti-cell-death
function of bcl-2 is impaired at a high level of expression [21].
Another interesting ¢nding is that the inhibition of caspase-
1 also coincides with an increase in the pro-apoptotic bax
Fig. 4. Western blot analysis of the expression pattern of bcl-2, bcl-
xL and bax in EGF-stimulated (25 ng/ml) AsPC-1 cells treated with
p-YVAD.CHO (25 WM) or DMSO alone for di¡erent incubation
times. Equal loading is con¢rmed by reprobing the gel with L-actin.
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protein expression levels in our examined AsPC-1 cells where-
as bcl-xL expression levels remained unchanged. This may be
consistent with the hypothesis that the ratio of bax/bcl-xL
expression levels determines the mode of cell death [22,23].
Shinoura et al. suggest that if a cancerous cell expresses a
level of bcl-xL which prevent bax-induced apoptosis, the over-
expression of bax leads to necrotic cell death [22]. Wood et al.
reported that cleavage of bax (21 kDa) into a 18 kDa protein
fragment enhances its cell-death function [24]. The lower pro-
tein band in the Western blot analysis of bax (Fig. 4) may
represent this 18 kDa protein fragment and support bax’s
function to shift the biochemical balance towards necrosis.
The observed upregulation of bcl-2 and bax expression lev-
els by unchanged bcl-xL levels in the pancreatic cell lines
AsPC-1, BxPC-3 and MiaPaCa-2 may support the suggestion
that the relative expression levels of bcl-2 family proteins to
each other is a crucial factor in the regulation of cell death. A
similar mechanism may also be assumed for the observed cell
death in Panc-1 cells although the protein ratios in these cells
cannot be determined because only very low levels of bcl-2
could be detected.
In conclusion, we have demonstrated the induction of a
‘necrotic-like’ cell death in EGF-stimulated, caspase-1-ex-
pressing, pancreatic cells by p-YVAD.CHO and a parallel
upregulation of protein expression levels of bcl-2 and bax.
Although the determination of the exact interrelations be-
tween the upregulation of bcl-2 and bax expression levels
and the observed cell death warrants further investigation, a
caspase-1-dependent modulation of the expression of these
proteins cannot be excluded. However, our results support
our previous suggestion that caspase-1 has an anti-cell-death
function in pancreatic carcinoma and may provide new as-
pects in the role of caspase-1 in cell proliferation and death.
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